France Point-of-Care Glucose Testing Market Size, Share, Competitive Landscape and Trend Analysis Report by Product Type, by Application, by End User : Opportunity Analysis and Industry Forecast, 2023-2032

The France point-of-care glucose testing market is expected to witness strong growth during the forecast period due to increase in demand for glucose testing from consumers and healthcare providers. The market is segmented into product type, application, and end user. On the basis of product type, the market is bifurcated into lancing devices & strips and blood-glucose meters. As per application, the market is divided into type-1 diabetes and type-2 diabetes. According to end user, the market is classified into hospitals & clinics, home care settings, and others. The home care settings segment is anticipated to witness surge in demand in the future owing to the availability of portable & easy-to-use mechanical devices and glucose test strips. 
 
Rise in prevalence of diabetes in France and surge in rate of obesity are the factors boosting the demand for point-of-care glucose testing. Majority of the population in France suffering from diabetes prefers finger pricking devices and glucose test strips to measure the level of glucose in the blood. This is anticipated to drive the market development during the forecast period. In addition, rise in trend of digital healthcare and increase in adoption of connected medical devices is projected to drive the France point-of-care glucose testing market. Furthermore, government initiatives such as tax benefits and subsidies are implemented boost the adoption of point-of-care glucose testing. Moreover, development in the retail sector and increase in research activities are expected to open new avenues for the market growth.  

However, there are certain restraints for the growth of the market, including availability of diabetic-friendly food products and limited access to affordable healthcare. On the contrary, the France point-of-care glucose testing market offers numerous growth opportunities for market players. The influx of innovative products such as glucose monitoring contact lenses and noninvasive blood glucose monitoring are expected to open new avenues for growth. Furthermore, deployment of Artificial Intelligence (AI) in testing devices is anticipated to unfold significant potential for development. Moreover, technological advancements such as cloud computing in healthcare are anticipated to propel the market growth. In addition, increase in R&D activities is projected to open new investment opportunities in various segments of the market. 

 
The market is expected to earn profits owing to surge in preference for telemedicine and increase in use of glucose test strips & 3D-printed wearables in home care settings. Moreover, the prevalence of lifestyle diseases and the need to lower healthcare costs are expected to drive the market. Key players operating in the France point-of-care glucose testing market adopt several strategies to gain one-upmanship. For instance, Abbott has launched a new point-of-care glucose testing device, the Armada, which provides accurate and reliable results in a short duration of time. The device features a touch-screen interface and easy-to-use components for accurate results. In addition, the company has signed an agreement for the establishment of a new distribution center in the country. In 2020, Roche Diagnostics launched ”GlycoMark” point-of-care glucose testing device. This device features a one-step sample collection method and offers precise results within minutes. Furthermore, the device can be integrated with portable devices, such as tablets, laptops, and smartphones. 

 
Arysta Lifescience aims to expand its geographical presence by launching the Arysta Glucose Monitor. This compact and portable device uses advanced technology to monitor glucose levels. In 2020, LifeScan launched its LifeScan OneTouch Ultra2 system in France. The attributes of the device include simple user interface, improved accuracy & convenience, bluetooth connectivity, and large backlit display. Sanofi has launched its A1C Now Plus point-of-care glucose testing system in France. This system includes a handheld device, a disposable connector, and a single-use blood collection cartridge. In addition, the device offers simultaneous testing for A1C, fasting glucose, and postprandial glucose in a single test. 

 

AgaMatrix has expanded its market presence by launching its new product, the WaveSense Eclipse Blood Glucose Monitoring System, which is equipped with advanced technology and provides accurate results within a few minutes. Nipro Diagnostics has launched its TrueResult point-of-care glucose testing system in France, which enables users to run glucose tests within 15 seconds. Moreover, the device features a small sample size and affordable pricing. Demeditec Diagnostics has launched its fast glucose test strips, which are suitable for both fasting and postprandial glucose testing. 

Key players operating in the France  point-of-care glucose testing market include Abbott, Roche Diagnostics, Arysta Lifescience, Lifescan, Sanofi, AgaMatrix, Nipro Diagnostics, Demeditec Diagnostics, Glucose Diagnostics and Acon Laboratories. 

 Key Benefits For Stakeholders

• Enable informed decision-making process and offer market analysis based on current market situation and estimated future trends.
• Analyze the key strategies adopted by major market players in France point-of-care glucose testing market.
• Assess and rank the top factors that are expected to affect the growth of France point-of-care glucose testing market.
• Top Player positioning provides a clear understanding of the present position of market players.
• Detailed analysis of the France point-of-care glucose testing market segmentation assists to determine the prevailing market opportunities.
• Identify key investment pockets for various offerings in the market.

  France Point-of-Care Glucose Testing Market Report Highlights